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Cancer is rapidly growing to be one of the major health burdens in Brazil and Latin America. Access to tumor samples
is one of the many barriers that need to be removed in order to promote clinical and translational research aimed at
developing and improving cancer prevention and treatment in this region. Although there is a growing interest
in establishing tumor collections in many hospitals and institutions, success is limited by the lack of knowledge
of the complexities of this activity. This article reviews the regulatory, pathology, and molecular aspects that are
relevant to the establishment of tumor banks in Brazil and Latin America. It also provides an overview of key players
in the region.
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For a long time, research in Brazil and Latin America
with human biological material had been restricted to
universities and a few teaching hospitals. Difficulties in
getting sufficient and long term research funding might
have accounted for a common characteristic among
these types of human biological collections: they were
exclusively project driven collections, usually accessed
only by those investigators involved in the research itself.
Applying a recently proposed schema for sample collec-
tions, they would be classified as mono-user or oligo-
user biobanks [1].
From the second half of the past century, some events
concurred to change this scenario. An increase in develop-
ment indicators led most countries in South America to
experience a socioeconomic transition. Despite the per-
sistent socioeconomic inequality, this transition led these
countries to face an aging population and a marked
change in the ranking of death causes [2]. In Brazil and
many other Latin American countries, cancer is now a
major cause of death, second only to cardiovascular dis-
eases. The technical advances and promises brought by
the endeavor to sequence the human genome in the late
nineties was the second event that led many institutions* Correspondence: ahcampos@accamargo.org.br
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common cancers in Latin American countries could be
studied. However, as opposed to the notion of “research
directed-use” associated with project driven collections –
which would require that patients knew exactly the
research objectives to which the collection of its biological
material is associated – this new biobanks proposed that
the collection of biological material were authorized for
future projects, whose specific objectives were not yet
known (“future undefined use”), and that would be con-
ducted by third parties (“poly-user biobanks”). This new
concept of “tissue donation” to a central core facility that
distributes samples to different projects/researchers brings
new ethical problems which are mainly related to issues
such as the right of privacy, the ownership and commer-
cial use of human biological material and right of access
to information.Main text
Regulatory aspects
In Brazil, it was felt that the existent legislation did not
take into account the differences, both in ethical and
operational terms, of these types of biobanks. As a
result, a new regulatory framework came into force in
2011 [3]. The Brazilian Guidelines for Biobanks and
Biorepositories dedicated to Health Research (Brazilian
Ministry of Health Ordinance 2201/11) and the National
Health Council Resolution CNS 441/11 (governing thele is distributed under the terms of the Creative Commons Attribution 4.0
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logical material) seek to recognize and better regulate
both mono/oligo-user and poly-user collections of human
biological material. Biobanks (defined in both normative
as an institutional facility dedicated to the systematic col-
lection of human biological material to support multiple,
future studies) need to be registered at the Brazilian
National Research Ethics Commission (CONEP). Since
2014 the ethical analysis of research projects that use
human biological material is put on hold if CONEP and/
or local ethics review boards find out that the samples
come from unregistered biobanks. To be recognized as
institutional biobanks, they must adopt a set of procedures
to standardize the collection, storage, processing and
distribution of human biological material, ensuring its
quality and fitness-for-purpose and also the individual
rights of donors.
It is expected that in the coming years specific national
regulations on biobanking will come into force in
Argentina, Chile and other countries in South America.
Until then, biobanking and the use of human samples in
research will be governed in these countries by specific
chapters from prior resolutions, decrees or laws enacted
for other purposes (such as those regulating transplant
banks or establishing general guidelines for research
involving human beings).
Tissue collection and storage requirements
For the biological material collected for biobanks to be
effectively used in translational research, special care must
be taken during the stages of collection and storage. In the
case of tissue samples, it must be kept in mind the poten-
tial end-use when defining the best preservation method.
Formalin-fixed and paraffin embedded (FFPE) tissues are
traditionally used in diagnostic pathology, considered the
gold-standard for the morphological preservation of
original tissue and can be used in techniques such as
immunohistochemistry, in situ hybridization and even
gene sequencing. However, depending on the molecule
of interest and molecular technique to be used, the
cryopreservation method is most suitable and has been
adopted by many biobanks. There are however crucial
factors that need to be controlled.
Cold ischemia is a major factor that can influence the
utility of banked samples. It is defined as the elapsed
time between the interruption of blood supply and cryo-
preservation of the tissue sample, and if not controlled
may result in significant global gene expression changes
[4–6]. Currently there is no universally accepted maximum
cold ischemia time [7, 8], and although the guidelines of
the A C Camargo Biobank suggest a maximum of 30 min,
collections that exceed this time are allowed in order to
detect and correct deviations from the maximum time
window. On average, 80% of the samples at the A CCamargo are collected within 30 min and the average
collection time for the role inventory of tissue samples
is 24 min.
Likewise, there is no universally accepted temperature
for the long-term preservation of frozen tissues. Although
many biobanks use −80 °C freezers, the International
Agency for Research on Cancer (IARC) recommends that
this temperature should be below – 130 °C (which is the
glass transition temperature of water) [7, 8]. In theory,
tissues that are quickly frozen and kept below this
temperature are free of any degradation of macromolecules
(e.g., hydrolysis or enzymatic degradation) [9–11]. In a re-
cent study, our group showed no significant change in RIN
(RNA Integrity Number) values of cryopreserved tissues
stored at −140 °C for up to 7 years [12]. On the other hand,
researchers at the Indiana University, examining sets of
samples that were stored at −80 °C observed that all sam-
ples with less than 18 months of storage had high-quality
RNA (also analyzed by RIN), compared to only 48% of the
samples that were stored for longer periods (>8 years) [8].
Currently, there is no published study that has compared
the quality of macromolecules extracted from tissues that
were submitted to the same collection and cryopreserva-
tion protocols and stored at −140 and −80 °C, so biobanks
that intend to store tissues for long periods of time should
consider adopt temperatures below −130 °C (either using
cryogenic freezers or liquid nitrogen containers) [11, 12].
Quality assurance – histology and molecular aspects
Histological review by a pathologist is needed to assure
that samples represent the tumor that is being banked,
and that non-neoplastic tissues represent the histological
counterpart of such tumor. Factors that may influence
the quality of the sample and the decision to use it in a
certain research include the percentage of viable tumor
cells, necrosis, and whether the tumor is infiltrating
non-neoplastic tissue in a manner that impedes enrich-
ment using a macrodissection technique [13].
Another critical issue in defining protocols for bio-
banking practices is the preservation of macromole-
cules for clinical and translational studies. Tissue
storage temperature, and the length of time that tissues
and purified RNA stay frozen, may directly impact
macromolecule preservation, particularly RNA. In the
same study in which our group analyzed the storage
conditions of tissues, the long-term preservation of
RNA molecules was also addressed. With respect to
RNA aliquots (which are stored at −80 °C), our results
shown that the concentration of stored RNA strongly
affects its integrity in long-term storage, indicating that
biobanks that intend to distribute not only tissues, but
also extracted RNA macromolecules for research must
also control this variable, storing RNA in high concen-
tration (>200 ng/μl) [12].
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In Brazil, three Tumor Banks can be regarded as key
biobank players. The Biobank of the A C Camargo
Cancer Center (A C Camargo Biobank) started as a
Tumor Tissue Bank in 1997 with the goal of providing
high quality annotated tumor and non-neoplastic sam-
ples to the then called Human Transcriptome Project. In
2004, a central facility for the extraction and distribution
of macromolecules (mainly DNA and RNA) was created,
in order to maximize the use of samples and to have a
more strict control of quality control metrics [13].
Another characteristic of this Biobank is the involvement
of surgical pathology residents in its sample procure-
ment activities, so that residents are exposed to the dif-
ferent technical as well as ethical aspects of biobanking.
With approximately 62,000 samples from 22,000
patients, the A C Camargo Biobank has provided sample
aliquots for approximately 50 different research projects
per year in the last three years (internal data as of
December 2015). Samples provided by this Biobank are
available to the A C Camargo Cancer Center research
staff as well as the general scientific community through
the establishment of research collaborations. Being the
first tumor bank to be created and certified in Brazil,
this biobank has been serving as a model for the estab-
lishment of other biobanks in Brazil as well as in other
South American countries.
The first public initiative to create a Tumor Bank was
carried out by the Brazilian National Cancer Intitute
(INCA) in 2004, and the first patient to provide samples
was included in 2005. Since then, the so called Brazilian
National Tumor and DNA Bank (BNT-INCA) has col-
lected 40,609 sample aliquots from 31,128 patients (as of
July 2016) [14]. BNT-INCA has initiatives to motivate
the creation of other public tumor banks in Brazil,
through the establishment of a Brazilian Network of
Tumor Banks. BNT-INCA is also part of a group of
tumor banks linked to the South American Network of
National Cancer Institutes (RINC/UNASUR). The so
called “Red de Biobancos de Latinoamérica y Caribe”
(REBLAC) was created in 2008 with the aim of establish-
ing tumor banks in public cancer care institutions, as
well as harmonizing operating procedures, and ethical/
legal guidelines within the scope of RINC/UNASUR
[15]. Together with BNT-INCA, 18 institutional Tumor
Banks from Argentina, Bolivia, Chile, Colombia,
Ecuador, México, Peru and Uruguay are members of
REBLAC. In 2015, REBLAC changed its policies to allow
nonpublic institutions to join the network. We have no
record of researches performed using samples collected
by REBLAC, possibly because currently there is no
common software for sample procurement among the
different biobanks. The REBLAC has been promoting
bi-annual meetings in which its members discuss thecurrent situation of the network, provide updates of
their biobanks and plan future actions. Some of the pro-
posed actions are: [15]
 To perform technical site visits in institutions that
have been recently incorporated in the network or
who intend to join in the near future.
 To provide training for professionals involved in
biobanking activities (pathologists, technicians,
nurses, TI analysts) at the BNT-INCA or the
National Cancer Institute of Colombia (“Banco
Nacional de Tumores Terry Fox”).
 To have at least two thematic workshops to
implement common technical procedures and
requirements for quality management and
accreditation/certification of participant biobanks.
The third tumor bank created in Brazil is the so called
“Banco de Tumores Ricardo Renzo Brentani”, located at
the Barretos Cancer Hospital, a tertiary non-profit cancer
care institution located in the city of Barretos, approxi-
mately 450 km distant from the city of Sao Paulo. The
Barretos Cancer Hospital is known as a reference cancer
center for nearby cities, as well as remote areas of the
country for patients without access to private health insur-
ance. This biobank was created in 2006, and, as of April
2014, had approximately 115,000 samples from diverse
origins (including paraffin blocks from the Department of
Anatomic Pathology) in its database. In 2013, approxi-
mately 8,000 samples had been used in different research
projects. Access to samples for external investigators are
granted through the establishment of research collabora-
tions, as occurs with the A C Camargo Biobank.
In Argentina, aside from the public biobanks that are as-
sociated to REBLAC, the Biobank of CEMIC (“Centro de
Educación Médica y Investigaciones Clínicas”, a medical
and research center located in the city of Buenos Aires)
was created in 2008 and also focuses in the collection of
tumors and non-neoplastic controls. To date, samples
from approximately 7,300 patients have been accrued (in-
cluding fresh-frozen tissue samples, FFPET and tissue-
derived DNA/RNA). Researches already performed have
focused in the clinical application of molecular biology for
the detection of micrometastasis (mainly from breast can-
cer, colon cancer and melanoma). Currently, researchers
from the A C Camargo Biobank and CEMIC collaborate
in the study of pre-analytical factors and their impact in
the quality of fresh-frozen tissue samples.
Conclusions
Challenges and future perspectives
With the exception of Brazil, research tumor banks in
other Latin American countries operate without specific
regulation. This may pose a problem for the execution
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active network of biobanks dedicated to the research of
a specific disease (like the above mentioned REBLAC,
which is still in the process of establishing minimum
technical standards and common rules for sample access
within the network). Widespread knowledge of existent/
future national regulations and efforts to identify mini-
mum common requirements will be mandatory to facili-
tate trans-border and overseas exchange of samples [16].
The Latin America region also needs to break out the
paradigm of public versus not-for profit private biobanks.
A common forum in which both types of biobanks can
participate is highly desirable, as well as a decisive move
towards integration in the international biobanking soci-
ety. Only the A C Camargo Biobank has representatives at
the International Society for Biological and Environmental
Repositories (ISBER), a global forum for sharing know-
ledge on biobanking [17]. We believe that the exchange of
ideas and experiences with other biobanking professionals,
as well as the sharing of difficulties, are a source of useful
information to improve daily operations.
An additional challenge is the absence of specific funding
for existent and future biobank initiatives. In Brazil, as well
in Argentina, human biological samples cannot be sold.
Although the adoption of a cost recovery model is recom-
mended, this alternative may prove insufficient to secure
long-term viability of institutional biobanks. Although in
Brazil the federal government and some states (particularly
the state of Sao Paulo) often provide funding for research-
related infrastructure (which could benefit biobanks), such
grants are limited in duration and the bulk of available
funding is directed at research projects focused on the
study of a single disease. This is in sharp contrast with the
philosophy of an institutional tumor bank, in which sam-
ples from several types of cancers are collected and stored
for future unrelated projects. In this particular field, in
which cancer samples need time to “mature” (i.e., to have
sufficient annotated information and patient follow up in
order to maximize their value for translational studies), the
current model of funding is clearly inadequate. This may
explain why a few biobanks in the South America region
have succeeded in establishing and maintaining their
operations, and accomplished their role of providing
samples to increase the quantity and quality of health
research done in South America.
As outlined throughout this chapter, there has been a
focus in the establishment of tumor banks in Brazil and
Latin America. However, there is a need to develop bio-
banks to support the study of a variety of diseases related
not only to the aging process observed in this region (e.g.,
neurologic and rheumatologic diseases) as well as those
that still pose a burden to the general population because
of persistent social inequality (e.g., infectious diseases).
There is also a clear need for biobanks aimed at providingsamples for the study of other lifestyle diseases related to
an increase in socioeconomic indicators, such as obesity
and diabetes. To date, due to their characteristics, the col-
lections in Brazil focused in the study of infectious or life-
style diseases (e.g. the so called “Projeto ELSA Brasil”)
[18], in spite of the number of samples, are classified by
Brazilian regulations as project-driven collections (“biore-
positories”) because access is restricted to a single
researcher or a single research group.
If tumor banks in Brazil and Latin America overcome
these challenges and really leave the cradle, they may
turn out to be invaluable resources for the study of
many human diseases, particularly in an era in which
the promise of personalized medicine needs to be based,
among other things, on a solid knowledge of the genetic
background of each population .
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